Study to Evaluate the Safety, Tolerance, Pharmacokinetics & Preliminary

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02846038` - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting	`NCT05159388` - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors	Phase 1/Phase 2
Completed	`NCT03181854` - Randomized Controlled Trial of Integrated Early Palliative Care	N/A
Recruiting	`NCT04107311` - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting	`NCT04078152` - Durvalumab Long-Term Safety and Efficacy Study	Phase 4
Completed	`NCT02250157` - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies	Phase 1
Recruiting	`NCT03943004` - Trial of DFP-14927 in Advanced Solid Tumors	Phase 1
Recruiting	`NCT04586335` - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Phase 1
Active, not recruiting	`NCT00479128` - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors	Phase 1
Recruiting	`NCT04143789` - Evaluation of AP-002 in Patients With Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT04550663` - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors	Phase 1
Active, not recruiting	`NCT03980041` - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Phase 2
Recruiting	`NCT04930432` - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05119907` - Sacituzumab Govitecan in Patients With Solid Tumor	Phase 2
Active, not recruiting	`NCT05046808` - Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects	Phase 1
Recruiting	`NCT04553692` - Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers	Phase 1
Recruiting	`NCT04096638` - Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT04180384` - A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients	Phase 2
Recruiting	`NCT04475523` - Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies	Phase 1

NCT number	NCT05199519
Study type	Interventional
Source	Innovent Biologics (Suzhou) Co. Ltd.
Contact	Jiahui Xu
Phone	+86 010 87705665
Email	[email protected]
Status	Recruiting
Phase	Phase 1
Start date	December 13, 2021
Completion date	December 13, 2023

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms